The DAISY Project
Descriptive register study to Asses the treatment reality of type 2 diabetes patients In Sweden
Thomas Nyström and David Nathanson diabetes researchers at the Department of Clinical Science and Education, Södersjukhuset are participating in the DAISY project, a collaboration between a number of clinically active diabetes researchers and Astra Zeneca.
The project carries out epidemiological research that aims to highlight the extent of type 2 diabetes and its harmful consequences, with main focus on cardiovascular disease and social costs.
The group also conducts, with modern epidemiological methods, studies that evaluate various antihyperglycemic agents effects on cardiovascular disease and risk of hypoglycaemia. In the studies published so far, data from the Prescribed Drug Register, the Patient Register and the Cause of Death Register are being used.
The project members have presented their work at several international conferences, including the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Two studies have been published, and more studies are currently in the analysis and script writing phase.
Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006–2013
Anna Norhammar, Johan Bodegård, Thomas Nyström, Marcus Thuresson, Jan W. Eriksson, David Nathanson
Diabetologia, May 2016
Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality
Jan W. Erikssona, Johan Bodegard, David Nathanson, Marcus Thuresson, Thomas Nyström, Anna Norhammar
Diabets Research and Clinical Practice , Volume 117, July 2016, Pages 39–47